|
|
Article: Press Statement Issued by Ranbaxy Laboratories Limited.
- Article from:
- PR Newswire
- Article date:
- February 25, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GURGAON, India, Feb. 25 /PRNewswire/ -- Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner.
The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with specifications upon testing.
No products from Ranbaxy's other manufacturing facilities are included in the AIP.
Ranbaxy will continue to co-operate with the ...